Clinical

Several measures of hemodynamic capacity were improved in this study that evaluated sacubitril/valsartan use for heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH).

Until recently, ophthalmologists in the United States have had no experience with biosimilars, despite the availability of biosimilars for bevacizumab, which is commonly used off label for ophthalmic conditions.

Results from a phase 2a study show that a bivalent prefusion F vaccine was effective against symptomatic respiratory syncytial virus (RSV) infection and viral shedding, with no identified safety concerns.

As the number of known cancer targets and precision therapies increases, implementing whole-genome sequencing (WGS) into regular clinical practice may benefit patients with metastatic cancer.

Previously, patients with low expression of HER2 were categorized as HER2-negative but adding the HER2-low classification creates new opportunities for patients with advanced breast cancer, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.

Each disease group guides and approves OneOncology clinical pathways to reflect evidenced-based national guidelines, which are updated often as new trial results are published or presented at major scientific meetings.

This systematic review found that studies of case management interventions have adequate quality and, in many cases, show cost-effective or even cost-saving results.

New data suggest motor function improves with amifampridine.

Dr Haumschild aligns payer considerations with molecular testing and biomarker application for treatment of patients with mCRC.

Our experts conclude with their final thoughts on the future of NSCLC treatment.

Three medical professionals recommend educational needs for both payers and providers within the NSCLC treatment landscape.

Drs Sabari and Spira comment on the use KRAS inhibitors in both frontline and combination therapies.

Dr Kristen Ciombor discusses utilization of biomarkers and molecular testing in the treatment of patients with CRC.

Posters presented at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting evaluated the association between long-term visual acuity outcomes and use of anti–vascular endothelial growth factor (VEGF) therapy, as well as patient and caregiver experience with ant-VEGF.

While anti–vascular endothelial growth factor (VEGF) therapy is the first-line treatment for diabetic macular edema (DME), a majority of patients discontinue therapy after 6 months and there is no consensus on the ideal dosing paradigm.

A machine learning model was able to predict visual outcomes and showed that the time from diagnosis to first treatment indicates visual improvement in patients with macular edema due to central retinal vein occlusion (CRVO).

A new review notes advances and remaining questions, and calls for better incorporation of data from veterans.

The tool could help clinicians better screen patients for adjuvant chemotherapy following curative resection for intrahepatic cholangiocarcinoma (ICC).

At the beginning of the pandemic, remote retinal imaging declined sharply due to a recommendation to stop nonessential eye care services in the first months of 2020, said Parisa Emami-Naeni, MD, MPH, assistant professor of ophthalmology at University of California, Davis, and vitreoretinal surgeon and uveitis specialist at UC Davis Eye Center.

Data show surgery leads to the best outcomes.

This article describes the findings of an observational study carried out in India to examine the clinical profile of individuals detected to be COVID-19 positive post vaccination.

After struggling for months with a Clostridioides difficile infection, Freda Pyles traveled from her home to rural Pennsylvania to Yale-New Haven Hospital in Connecticut for the therapy that ultimately healed her.

A recent study characterized the known association between corticosteroid exposure and type 2 diabetes (T2D), finding risk to be associated with treatment- and patient-related characteristics that can inform prescription of treatment with steroids.

The combination regimen delivered better overall survival and response rates among patients with myelodysplastic syndromes (MDS).